Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Jaccard, Arnaud  [Clear All Filters]
Journal Article
Coignard-Biehler H, Mahlaoui N, Pilmis B, Barlogis V, Brosselin P, De Vergnes N, Debré M, Malphettes M, Frange P, Catherinot E, et al. A 1-Year Prospective French Nationwide Study of Emergency Hospital Admissions in Children and Adults with Primary Immunodeficiency. J Clin Immunol. 2019.
Berning P, Schmitz N, Ngoya M, Finel H, Boumendil A, Wang F, Huang X-J, Hermine O, Philippe L, Couronné L, et al. Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis. Leukemia. 2023.
Le Borgne A, Prévot G, Rouquette I, Huynh A, Têtu L, Projetti F, Carreiro M, Borie R, Jaccard A, Recher C, et al. Blood stem cell transplantation to treat cystic lung light chain deposition disease. Eur Respir J. 2015.
Roussel M, Moreau P, Hébraud B, Laribi K, Jaccard A, Dib M, Slama B, Dorvaux V, Royer B, Frenzel L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial. Lancet Haematol. 2020;7(12):e874-e883.
Van de Wyngaert Z, Nerich V, Fouquet G, Chrétien M-L, Caillot D, Azar N, Garderet L, Lenain P, Macro M, Bourhis J-H, et al. Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma. Bone Marrow Transplant. 2020.
Palladini G, Schönland S, Merlini G, Milani P, Jaccard A, Bridoux F, Dimopoulos MA, Ravichandran S, Hegenbart U, Roeloffzen W, et al. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018. Blood Cancer J. 2023;13(1):19.
Le Gouill S, Beldi-Ferchiou A, Alcantara M, Cacheux V, Safar V, Burroni B, Guidez S, Gastinne T, Canioni D, Thieblemont C, et al. Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group. Lancet Haematol. 2020.